Device Overview

Technical Specifications

Core Technology:

• Electric breakdown: ~3000 V per mm

• Optimal distance: 0.5mm from tissue

• Probe tip width: 0.5mm

• Mechanism: Sublimation (solid to gas) without heat transfer

Hardware:

• Three wireless handpieces: White, Green, Red (calibrated for different power levels)

• White handpiece (ophthalmology): 0.7-watt power

• Touch display with multilingual software

• Wireless charging base

• Operating duration: up to 8 hours

Mechanism of Action:

• Generates Reactive Oxygen and Nitrogen Species (RONS)

• Stimulates Type III collagen regeneration

• Causes controlled tissue contraction

• No return electrode needed (unlike electrosurgery)

• Lower power than electrosurgical units

Regulatory Status:

• FDA cleared: skin lesion removal and tissue coagulation

• CE certified (Europe)

• TGA listed (Australia)

• Health Canada licensed (first fully licensed plasma technology, 2021)

• Distributed in 60+ countries

Clinical Evidence:

• 40+ scientific publications

• 12+ years clinical use

• Millions of treatments performed worldwide

Ophthalmological Applications

PANIS Method

Plasma-Assisted Noninvasive Surgery - developed by Iranian Vision Research Center for ocular surface disorders using Plexr Plus technology.

Treatable Pathologies

1. Dermatochalasis (Non-Surgical Blepharoplasty)

• Pathology: Drooping eyelid skin, age-related laxity

• Plexr Plus Results: 100% improvement rate, +2.6 grade increase, immediate visible results lasting years, 30-35% improvement per session

2. Conjunctivochalasis

• Pathology: Loose redundant conjunctiva causing tearing, irritation

• Plexr Plus Results: Grade 3-4 reduced to grade 1-2 in 1 month, all normalized at 6 months, no recurrence, 5-10 minute procedure

3. Pterygium

• Pathology: Fibrovascular growth onto cornea from UV exposure

• Plexr Plus Results: Improved visual acuity, no sutures/glue needed, few minutes procedure (vs. 30 min traditional), 0-33% recurrence rates

4. Conjunctival Nevus

• Pathology: Benign melanocytic tumor

• Plexr Plus Results: Complete disappearance outside limbus, size reduced from 3.89×11.7mm to 0.54×1.69mm, no recurrence, no complications

5. Dry Eye (Punctal Occlusion)

• Pathology: Aqueous deficient dry eye

• Plexr Plus Results: TMH +79.8%, TBUT +69.99%, Schirmer +86.20%, sustained 3-6 months, no foreign body sensation vs. plugs

6. Conjunctival Cyst

• Pathology: Fluid-filled epithelial inclusion cysts

• Plexr Plus Results: 100% complete healing, no recurrence, no complications, no scarring

7. Chalazion

• Pathology: Meibomian gland obstruction/inflammation

• Plexr Plus Application: Alternative to incision/curettage for chronic cases, minimally invasive drainage

8. Entropion

• Pathology: Inward turning eyelid causing corneal irritation

• Plexr Plus Application: Tissue tightening for mild involutional cases, adjunct to correct malposition

9. Conjunctival Stria

• Pathology: Linear conjunctival folds from laxity

• Plexr Plus Application: Tissue shrinkage and remodeling to reduce striations

Key Advantages of Plexr Plus

vs. Surgery:

• No operating room, no general anesthesia, no incisions

• Office-based procedures

• 1-2 day recovery vs. weeks

• Lower cost

vs. Other Energy Devices:

• No heat conduction to surrounding tissue

• More precise (0.5mm tip)

• Safer for periocular/ocular surface

• No return electrode

Clinical Benefits:

• Single device, multiple applications

• Topical anesthesia only

• 5-30 minute procedures

• Immediate results

• Minimal complications

Safety Profile:

• Superficial action preserves deep structures

• No thermal damage to underlying tissue

• Minimal bleeding/inflammation

• 7-14 day healing

Summary

Plexr Plus treats 9 ophthalmological pathologies:

• 2 eyelid disorders

• 5 conjunctival surface disorders

• 2 functional/glandular disorders

Device uniqueness: Wireless handpieces, 0.7W white handpiece for ophthalmology, precise 0.5mm tip, no heat spread, extensive global validation (40+ publications, 60+ countries, 12+ years use).